Früherkennung des sporadischen Pankreasadenokarzinoms

Zusammenfassung

Das Pankreasadenokarzinom (PK) nimmt stetig an Häufigkeit zu und stellt bereits die dritthäufigste tumorbedingte Todesursache in Deutschland dar. Voraussichtlich rückt es bis 2030 auf den 2. Platz und bis 2050 gar auf den 1. Platz der krebsbedingten Todesfälle vor. Das Pankreaskarzinom wird generell spät diagnostiziert und die 5-Jahre-Überlebensrate liegt bei nur 10%. Wird das PK aber im Tumorstadium IA diagnostiziert und therapiert, so beträgt das 5-Jahresüberleben rund 80%. Früherkennungsinitiativen verfolgen deshalb das Ziel, Hochrisikopersonen zu identifizieren und das sporadische Pankreaskarzinom frühzeitig festzustellen. Personen über 50 mit neu diagnostiziertem Diabetes stehen dabei im Mittelpunkt des Interesses. Aktuelle Entwicklungen und Früherkennungsstrategien werden angesprochen.

Abstract

The incidence of pancreatic cancer is rising. At present, pancreatic cancer is the third most common cancer-causing death in Germany, but it is expected to become the second in 2030 and finally the leading cause of cancer death in 2050. Pancreatic ductal adenocarcinoma (PC) is generally diagnosed at advanced stages, and 5-year-survival has remained poor. Early detection of sporadic PC at stage IA, however, can yield a 5-year-survival rate of about 80%. Early detection initiatives aim at identifying persons at high risk. People with new-onset diabetes at age 50 or older have attracted much interest. Novel strategies regarding how to detect sporadic PC at an early stage are being discussed.

Schlüsselwörter

Tumor - Screening - Diabetes - Neoplasie - Pankreas - Biomarker - Endosonografie - künstliche Intelligenz

Keywords

tumor - screening - diabetes - neoplasia - pancreas - biomarker - endoscopic ultrasound - artificial intelligence

Publication History

Received: 26 December 2022

Accepted after revision: 21 June 2023

Article published online:
12 October 2023

• Literatur

• 1 https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/Tabellen/sterbefaelle-krebs-insgesamt.html
• 2 Carioli G, Malvezzi M, Bertuccio P. et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol 2021; 32: 478-487
• 3 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-47
• 4 The Lancet Gastroenterology Hepatology. Pancreatic cancer: a state of emergency?. Lancet Gastroenterol Hepatol 2021; 6 (02) 81
• 5 Blackford AL, Canto MI, Klein AP. et al. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Int 2020; 112: 1162-1169
• 6 Pereira SP, Oldfield L, Ney A. et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol 2020; 5: 698-710
• 7 https://www.awmf.org/uploads/tx_szleitlinien/032–010OLl_Exokrines-Pankreaskarzinom_2022–01.pdf
• 8 Sawhney MS, Calderwood AH, Thosani NC. et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc 2022; 95 (05) 817-826
• 9 Dbouk M, Brewer Gutierrez OI, Lennon AM. et al. Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements. Pancreatology 2021; 21: 613-621
• 10 Tonini V, Zanni M. Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe. World J Gastroenterol 2022; 28 (31) 4235-4248
• 11 Kim YJ, Oh CM, Park SK. et al. Fasting blood glucose and risk of incident pancreatic cancer. PLoS One 2022; 17 (10) e0274195
• 12 Khadka R, Tian W, Hao X. et al. Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review. Int J Surg 2018; 52: 342-346
• 13 Yuan C, Babic A, Khalaf N. et al. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol 2020; 6 (10) e202948
• 14 Chari ST, Andersen DK. Metabolic Surveillance for Those at High Risk for Developing Pancreatic Cancer. Gastroenterology 2021; 161: 1379-1380
• 15 Sharma A, Smyrk TC, Levy MJ. et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology 2018; 155: 490-500.e2
• 16 Lemanska A, Price CA, Jeffreys N. et al. BMI and HbA1c are metabolic markers for pancreatic cancer: Matched case-control study using a UK primary care database. PLoS One 2022; 17 (10) e0275369
• 17 Dbouk M, Katona BW, Brand RE. et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol 2022; 40 (28) 3257-3266
• 18 Klatte DCF, Boekestijn B, Wasser MNJM. et al. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. J Clin Oncol 2022; 40 (28) 3267-3277
• 19 Takikawa T, Kikuta K, Hamada S. et al. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Sci Rep 2022; 12 (01) 4262
• 20 Overbeek KA, Levink IJM, Koopmann BDM. et al. Dutch Familial Pancreatic Cancer Surveillance Study Group. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut 2022; 71 (06) 1152-1160
• 21 Overbeek KA, Goggins MG, Dbouk M. et al. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology 2022; 162 (03) 772-785.e4
• 22 Chhoda A, Vodusek Z, Wattamwar K. et al. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2022; 162 (03) 786-798
• 23 Rosenthal MH, Wolpin BM, Yurgelun MB. Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build. Gastroenterology 2022; 162 (03) 700-702
• 24 Yurgelun MB. Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals. J Clin Oncol 2022; 40 (28) 3230-3234
• 25 Umar N, Kamran U, Sia M. et al. How often is pancreatic cancer missed on CT or MRI imaging? A novel root cause analysis system to establish the most plausible explanation for post imaging pancreatic cancer. Presented at UEG Week 2022; 11 October 2022; Vienna, Austria.
• 26 Chen PT, Wu T, Wang P. et al. Pancreatic Cancer Detection on CT Scans with Deep Learning: A Nationwide Population-based Study. Radiology 2022; 306 (01) 220152
• 27 Parajuli P, Nguyen TL, Prunier C. et al. Pancreatic cancer triggers diabetes through TGF-β–mediated selective depletion of islet β-cells. Life Sci Alliance 2020; 3 (06) e201900573
• 28 Pang W, Yao W, Dai X. et al. Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2. Int J Biol Sci 2021; 17: 3622-3633
• 29 Su J, Pang W, Zhang A. et al. Exosomal miR-19a decreases insulin production by targeting Neurod1 in pancreatic cancer associated diabetes. Mol Biol Rep 2022; 49: 1711-1720
• 30 Xu YF, Hannafon BN, Zhao YD. et al. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. Oncotarget 2017; 8: 77028-77040
• 31 Li J, Li Y, Chen S. et al. Highly Sensitive Exosome Detection for Early Diagnosis of Pancreatic Cancer Using Immunoassay Based on Hierarchical Surface-Enhanced Raman Scattering Substrate. Small Methods 2022; 6: e2200154
• 32 Channon LM, Tyma VM, Xu Z. et al. Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer. Biochim Biophys Acta Rev Cancer 2022; 1877 (03) 188728
• 33 Chen J, Yao D, Chen W. et al. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer. Int J Biol Markers 2022; 37: 74-80
• 34 Nam H, Hong SS, Jung KH. et al. A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. J Natl Cancer Inst 2022; 114: 228-234
• 35 Hinestrosa JP, Kurzrock R, Lewis JM. et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond) 2022; 2: 29
• 36 Ferguson S, Yang KS, Zelga P. et al. Single-EV analysis (sEVA) of mutated proteins allows detection of stage 1 pancreatic cancer. Sci Adv 2022; 8 (16) eabm3453
• 37 Yoshioka Y, Shimomura M, Saito K. et al. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer. Cancer Sci 2022; 113 (10) 3498-3509
• 38 Singhi AD, Wood LD. Early detection of pancreatic cancer using DNA-based molecular approaches. Nat Rev Gastroenterol Hepatol 2021; 18 (07) 457-468
• 39 Wu H, Ou S, Zhang H. et al. Advances in biomarkers and techniques for pancreatic cancer diagnosis. Cancer Cell Int
• 40 Brand RE, Persson J, Bratlie SO. et al. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Clin Transl Gastroenterol 2022; 13 (03) e00468
• 41 Kuwatani M, Sakamoto N. Pathological and molecular diagnoses of early cancer with bile and pancreatic juice. Dig Endosc 2022; 34 (07) 1340-1355
• 42 Nakamura K, Zhu Z, Roy S. et al. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Gastroenterology 2022; 163 (05) 1252-1266.e2
• 43 Debernardi S, Blyuss O, Rycyk D. et al. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis. Int J Cancer 2023; 152 (04) 769-780
• 44 Makler A, Narayanan R, Asghar W. An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma. Biosensors (Basel) 2022; 12 (10) 831
• 45 https://www.morningstar.com/news/business-wire/20221221005065/bluestar-genomics-advances-to-commercial-phase-rebrands-as-clearnote-health
• 46 https://www.reuters.com/business/healthcare-pharmaceuticals/japanese-biotech-firm-uses-tiny-worms-test-pancreatic-cancer-2022–11–30/
• 47 https://immunoviainc.com/immunovia-strengthens-us-organization-to-continue-commercialization-of-its-novel-immray-pancan-d-test/
• 48 Kartal E, Schmidt TSB, Molina-Montes E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022; 71 (07) 1359-1372
• 49 Nagata N, Nishijima S, Kojima Y. et al. Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. Gastroenterology 2022; 163: 222-238
• 50 Daley D. The role of the microbiome in pancreatic oncogenesis. Int Immunol 2022; 34 (09) 447-454
• 51 Kotsiliti E. Microbial signatures in pancreatic cancer. Nat Rev Gastroenterol Hepatol 2022; 19 (06) 350
• 52 Herremans KM, Riner AN, Cameron ME. et al. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Microbiome 2022; 10 (01) 93
• 53 Kohi S, Macgregor-Das A, Dbouk M. et al. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2022; 20 (02) e196-e227
• 54 Kang JD, Clarke SE, Costa AF. Factors associated with missed and misinterpreted cases of pancreatic ductal adenocarcinoma. Eur Radiol 2021; 31 (04) 2422-2432
• 55 Mukherjee S, Patra A, Khasawneh H. et al. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diagnosis. Gastroenterology 2022; 163: 1435-1446.e3
• 56 Chen PT, Wu T, Wang P. et al. Pancreatic Cancer Detection on CT Scans with Deep Learning: A Nationwide Population-based Study. Radiology 2023; 306 (01) 172-182
• 57 Qureshi TA, Gaddam S, Wachsman AM. et al. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images. Cancer Biomark 2022; 33: 211-217
• 58 Javed S, Qureshi TA, Gaddam S. et al. Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images. Front Oncol 2022; 12: 1007990
• 59 Bian Y, Zheng Z, Fang X. et al. Artificial Intelligence to Predict Lymph Node Metastasis at CT in Pancreatic Ductal Adenocarcinoma. Radiology 2023; 306 (01) 160-169
• 60 Boursi B, Patalon T, Webb M. et al. Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model: A Retrospective Cohort Study Using Real-World Data. Pancreas 2022; 51: 196-199
• 61 Sharma S, Tapper WJ, Collins A. et al. Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Gastroenterology 2022; 162: 1665-1674.e2
• 62 Mellenthin C, Balaban VD, Dugic A. et al. Risk Factors for Pancreatic Cancer in Patients with New-Onset Diabetes: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022; 14 (19) 4684
• 63 Kitano M, Yoshida T, Itonaga M. et al. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer.. J Gastroenterol 2019; 54 (01) 19-32
• 64 van Riet PA, Erler NS, Bruno MJ. et al. Comparison of fine-needle aspiration and fine-needle biopsy devices for endoscopic ultrasound-guided sampling of solid lesions: a systemic review and meta-analysis. Endoscopy 2021; 53 (04) 411-423
• 65 Nakaoka K, Ohno E, Kawabe N. et al. Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. Diagnostics (Basel) 2023; 13 (02) 215
• 66 Ignee A, Jenssen C, Arcidiacono PG. et al. Endoscopic ultrasound elastography of small solid pancreatic lesions: A multicenter study. Endoscopy 2018; 50: 1071-1079
• 67 Kataoka K, Ishikawa T, Ohno E. et al. Endoscopic ultrasound elastography for small solid pancreatic lesions with or without main pancreatic duct dilatation. Pancreatology 2021; 21 (02) 451-458
• 68 Shin CM, Villa E. The efficiency of contrast-enhanced endoscopic ultrasound (EUS) combined with EUS elastography for pancreatic cancer diagnosis: a systematic review and meta-analysis. Ultrasonography 2023; 42 (01) 20-30
• 69 Goyal H, Sherazi SAA, Gupta S. et al. Application of artificial intelligence in diagnosis of pancreatic malignancies by endoscopic ultrasound: a systemic review. Therap Adv Gastroenterol 2022; 15
• 70 Dumitrescu EA, Ungureanu BS, Cazacu IM. et al. Diagnostic Value of Artificial Intelligence-Assisted Endoscopic Ultrasound for Pancreatic Cancer: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2022; 12 (02) 309
• 71 Scherübl H. Prävention des Pankreaskarzinoms. Dtsch Med Wochenschr 2023; 148 (05) 246-252